0R1F Panoramica delle azioni Bristol-Myers Squibb Company scopre, sviluppa, concede in licenza, produce, commercializza, distribuisce e vende prodotti biofarmaceutici in tutto il mondo. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Bristol-Myers Squibb Company Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Bristol-Myers Squibb Prezzi storici delle azioni Prezzo attuale dell'azione US$56.99 Massimo di 52 settimane US$61.07 Minimo di 52 settimane US$39.35 Beta 0.44 Variazione di 1 mese -3.23% Variazione a 3 mesi 5.85% Variazione di 1 anno 9.61% Variazione a 3 anni -7.25% Variazione a 5 anni -12.77% Variazione dall'IPO 1.82%
Notizie e aggiornamenti recenti
Upcoming dividend of US$0.62 per share Dec 30
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications Dec 28 Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025 Dec 19
Third quarter dividend increased to US$0.62 Dec 16
Bristol Myers Squibb Company Declares Quarterly Dividend, Payable on February 3, 2025 Dec 12 Vedi altri aggiornamenti
Upcoming dividend of US$0.62 per share Dec 30
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications Dec 28 Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025 Dec 19
Third quarter dividend increased to US$0.62 Dec 16
Bristol Myers Squibb Company Declares Quarterly Dividend, Payable on February 3, 2025 Dec 12
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline Dec 10
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms Nov 20
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors Nov 16
Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024 Nov 12 Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024
Third quarter 2024 earnings released: EPS: US$0.60 (vs US$0.94 in 3Q 2023) Nov 01
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024 Oct 28
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) Oct 04
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting Sep 29
Upcoming dividend of US$0.60 per share Sep 27
U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Sep 27 Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis Sep 18
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma Sep 16
Second quarter dividend of US$0.60 announced Sep 13
Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024 Sep 12
Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Sep 02
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma Aug 21 European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Aug 19
Second quarter 2024 earnings released: EPS: US$0.83 (vs US$0.99 in 2Q 2023) Jul 27 Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024 Jul 26
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma Jul 20
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Jun 22 Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024
First quarter dividend of US$0.60 announced Jun 20
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024 Jun 19 Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024 Jun 18
Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial Jun 06 Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma Jun 01
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine May 30
Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis May 18 Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma May 17
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial May 11
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) May 08
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer May 07
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma Apr 27
First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023) Apr 26
Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Apr 10
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Apr 06
European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept) Apr 03 Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease
Upcoming dividend of US$0.60 per share Mar 28
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Mar 27 Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024 Mar 19 Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others. Mar 18
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy Mar 16
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Mar 15
Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024 Mar 12
Fourth quarter dividend of US$0.60 announced Mar 10
U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo Mar 08
Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB). Feb 27 Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB). Feb 26
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS) Feb 23
Bristol Myers Squibb Announces U.S. Food and Drug Administration (FDA) Accepts for Priority Review the Supplemental New Drug Application (sNDA) for KRAZATI (adagrasib) in Combination with Cetuximab for the Treatment of Patients with Previously Treated KRASG12C-Mutated Locally Advanced or Metastatic Colorectal Cancer Feb 22
Bristol-Myers Squibb Company Announces Management Changes Feb 16
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors Feb 15
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer Feb 10
Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study Feb 06
Full year 2023 earnings released: EPS: US$3.88 (vs US$2.97 in FY 2022) Feb 02
Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi Jan 31
Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial Jan 28
Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Jan 26 Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib) Rendimenti per gli azionisti 0R1F GB Pharmaceuticals GB Mercato 7D -1.2% 1.8% 1.3% 1Y 9.6% -4.5% 4.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 0R1F ha superato il UK Pharmaceuticals che ha restituito -4.5 % nell'ultimo anno.
Rendimento vs Mercato: 0R1F ha superato il mercato UK che ha restituito 4.3 % nell'ultimo anno.
Volatilità dei prezzi Is 0R1F's price volatile compared to industry and market? 0R1F volatility 0R1F Average Weekly Movement 4.5% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Prezzo delle azioni stabile: 0R1F non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di 0R1F è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1887 34,100 Chris Boerner www.bms.com
Bristol-Myers Squibb Company scopre, sviluppa, concede in licenza, produce, commercializza, distribuisce e vende prodotti biofarmaceutici in tutto il mondo. Offre prodotti per malattie ematologiche, oncologiche, cardiovascolari, immunologiche, fibrotiche e neuroscientifiche. I prodotti dell'azienda includono Eliquis per la riduzione del rischio di ictus/embolia sistemica nella fibrillazione atriale non valvolare e per il trattamento di TVP/PE; Opdivo per varie indicazioni antitumorali, tra cui il cancro della vescica, del sangue, del CRC, della testa e del collo, RCC, HCC, del polmone, del melanoma, MPM, dello stomaco e dell'esofago; Pomalyst/Imnovid per il mieloma multiplo; Orencia per l'artrite reumatoide attiva e l'artrite psoriasica; e Sprycel per il trattamento della leucemia mieloide cronica positiva al cromosoma Philadelphia.
Mostra di più Bristol-Myers Squibb Company Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Bristol-Myers Squibb con la sua capitalizzazione di mercato? 0R1F statistiche fondamentali Capitalizzazione di mercato US$114.71b Guadagni(TTM ) -US$7.26b Ricavi(TTM ) US$47.44b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 0R1F Conto economico (TTM ) Ricavi US$47.44b Costo del fatturato US$11.44b Profitto lordo US$35.99b Altre spese US$43.25b Guadagni -US$7.26b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Feb 06, 2025
Utile per azione (EPS) -3.58 Margine lordo 75.87% Margine di profitto netto -15.30% Rapporto debito/patrimonio netto 289.5%
Come si è comportato 0R1F nel lungo periodo?
Vedi performance storica e confronto Dividendi
4.4% Rendimento attuale del dividendo
-67% Rapporto di remunerazione Quando è necessario acquistare 0R1F per ricevere un dividendo imminente? Bristol-Myers Squibb date dei dividendi Data di stacco del dividendo Jan 03 2025 Data di pagamento dei dividendi Feb 03 2025 Giorni fino al dividendo Ex 0 days Giorni prima della data di pagamento dei dividendi 31 days
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 08:12 Prezzo dell'azione a fine giornata 2025/01/02 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Bristol-Myers Squibb Company è coperta da 51 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione David Toung Argus Research Company Ishan Majumdar Baptista Research Charles Butler Barclays
Mostra 48 altri analisti 
